What Compounded and Brand Name GLP-1 Costs Each Month

Some links on our site may earn us a commission at no extra cost to you. Learn more.

Published July 12, 2026. Updated October 10, 2026.

Medical Disclaimer: We are not doctors, pharmacists, or medical professionals, and nothing in this comparison is medical advice. This is independent editorial content for informational purposes only. GLP-1 medications are prescription-only — a licensed clinician determines eligibility and which medication, if any, is appropriate. Compounded medications are not FDA-approved, and as of 2026 their availability is legally narrower than it was in 2023–2024. Individual results vary, and weight loss is never guaranteed.

Compounded brand name GLP-1 pricing is a closer call than it used to be. Compounded semaglutide runs about 57% of the Wegovy pen’s self-pay price, the new Wegovy pill starts below it, and compounded tirzepatide now sits close to Zepbound’s own tiers. The real bill is a running ledger of line items, not one price. That ledger changed in the past year because Novo Nordisk and Eli Lilly both sell directly to self-pay patients. Every real cost is itemized below, with current pricing taken straight from the manufacturers’ own pharmacy programs.

Compounded vs brand name: what does getting started cost?

Both paths start with a prescriber sign-off. No route skips that step. Many compounded telehealth platforms fold the intake consultation into one flat monthly price. That bundled fee covers consultation, medication, supplies, shipping, and monitoring. It commonly runs $199–$349 a month, per publicly advertised rates across several such platforms.

The brand-name route through your own doctor or an existing insurance relationship may add a separate office-visit cost outside this ledger. Manufacturer telehealth partners usually roll the consult into their own program fee. NovoCare Pharmacy lists Costco, GoodRx, WeightWatchers, Ro, LifeMD, and eMed among its partners.

Compounded vs brand name: what does the medication cost?

Both semaglutide and tirzepatide are FDA-labeled as once-weekly injections. A 28-day supply is therefore four doses, which is the basis for the per-dose math below. The Wegovy pen and pill figures were re-read on Novo Nordisk’s NovoCare Pharmacy site on October 10, 2026. The Zepbound figures were verified on Eli Lilly’s LillyDirect site in August 2026.

Novo Nordisk’s NovoCare Pharmacy prices self-pay Wegovy pens at $349/month for every dose from 0.25mg through the 2.4mg maintenance dose, after a $199/month introductory price on the first two 0.25mg and 0.5mg fills. That works out to $349 ÷ 4 = $87.25 per weekly dose. Eli Lilly’s LillyDirect prices self-pay Zepbound vials starting at $299/month for the 2.5mg starting dose, or $74.75 per dose. Maintenance doses cost more, up to $449/month through its Journey Program refill timing, or $112.25 per dose.

NovoCare Pharmacy also sells a Wegovy pill for self-pay. Its pharmacy page lists $149 a month at 1.5mg, $199 at 4mg and $299 at 9mg and 25mg, and defines one month as a bottle of 30 tablets. That is $149 ÷ 30 = about $4.97 a tablet at the lowest tier and $299 ÷ 30 = about $9.97 at the top.

How big is the compounded vs brand name GLP-1 price gap?

Compounded pricing at telehealth platforms in this space commonly runs $199/month for semaglutide ($49.75 per dose) and $349/month for tirzepatide ($87.25 per dose). Both are typically flat regardless of dose. The gap has narrowed a lot. Compounded semaglutide runs about 57% of the Wegovy pen price, at $199 vs. $349/month ($199 ÷ $349 = 0.57). Against the Wegovy pill it is no longer the cheap route at the start. $199 is about 34% more than the pill’s $149 tier ($199 ÷ $149 = 1.34) and about 67% of its $299 top tier ($199 ÷ $299 = 0.67). For tirzepatide, the gap has nearly closed. A typical flat compounded rate of $349/month sits close to Zepbound’s own $299–$449 self-pay tiers.

Do you need to buy syringes and other supplies?

It depends on the delivery device. Brand-name pens, the standard Wegovy and Ozempic delivery device, are pre-filled and need no separate needle purchase. Zepbound vials and vial-based compounded products both need separate syringes, alcohol swabs, and sharps disposal unless the provider bundles them. Many flat-fee compounded programs include supplies in the price. A self-supplied vial route can add $10–$20/month at a pharmacy.

What do monitoring and follow-up visits cost?

Ongoing check-ins, dose-adjustment reviews, and any lab work your clinician orders are a real recurring cost on either path. Compounded telehealth subscriptions typically bundle basic monitoring into the flat monthly fee. Brand-name self-pay through NovoCare or LillyDirect still requires a prescribing relationship with a clinician. That clinician’s visit or telehealth-partner fee sits outside the pharmacy price quoted above. Budget for it separately rather than assuming the medication price is the whole bill.

Is compounded GLP-1 still legal after the shortage ended?

Yes, but the legal basis is much narrower than it was in 2023–2024. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. The shortage-based exception that let compounding pharmacies mass-produce copies of these drugs during 2022–2024 no longer broadly applies.

As of April 1, 2026, the FDA states it will take enforcement action against compounders producing “essentially copies” of commercially available semaglutide or tirzepatide “regularly or in inordinate amounts.” A narrow carve-out covers pharmacies filling four or fewer prescriptions of a given compounded product per month. It also covers pharmacies documenting a genuine personalized-dose need that a commercial product can’t meet.

On April 30, 2026, the FDA went further. It proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the list that allows large-scale 503B outsourcing facilities to compound them at all. If finalized, that would close the door even if a future shortage occurred. The FDA has also linked compounded semaglutide to more than 455 adverse event reports, many involving dosing errors from self-administered multi-dose vials.

None of this means every compounded product on the market today is unsafe or illegal. 503A pharmacies can still legally compound personalized, non-standard doses for a documented individual medical need. But the wide-open “cheap copy of the brand drug for anyone who wants one” market of 2023–2024 is legally narrower now, and getting narrower. This article makes no claim about any specific compounded telehealth provider’s compliance status. If you’re considering a compounded option, ask the platform directly how it stays compliant with the post-shortage rules. Confirm the dispensing pharmacy’s state license before paying anything.

Why does the GLP-1 bill rise during dose escalation?

Both drug classes are typically titrated upward over several months rather than started at a maintenance dose. On the brand-name side, LillyDirect’s published tiers show the bill rising in step. They run $299/month at the 2.5mg starting dose, $399/month at 5mg, then $449/month at 7.5mg and above under its Journey Program refill timing. Without that refill timing, the same higher doses run $499–$699/month.

A patient titrating from 2.5mg to a 7.5mg maintenance dose would pay roughly $299 (month 1) + $399 (month 2) + $449 × 10 (months 3–12) = $5,188 in the first year. That is noticeably more than a flat monthly rate suggests. Compounded pricing at flat-fee telehealth platforms is often the same at every dose, so each month costs the same.

What does a full year cost, compounded vs brand name?

Here is what a full year costs at the medication line alone. Supplies, consults, and monitoring vary too much by provider to total honestly, so see the sections above for those separately.

Prices are approximate, current as of publication, and change frequently — confirm the latest price directly with NovoCare Pharmacy, LillyDirect, or your chosen compounded telehealth provider before budgeting.

Which should you pick, compounded vs brand name?

Brand-name self-pay fits you if you want an FDA-approved finished product and can absorb roughly $1,800–$5,200 a year, depending on pill, pen or Zepbound and the dose. That is a real cost, but far closer to compounded pricing than it used to be now that both manufacturers sell direct. Compounded fits you if the brand-name price is still out of reach and you do the vetting. Confirm the pharmacy you’re considering is licensed. Ask how it complies with the FDA’s post-shortage compounding rules. Get a plain answer on FDA status before paying anything. Skip both if a licensed clinician hasn’t evaluated whether GLP-1 treatment is appropriate for you. That is the gate everything else in this ledger waits behind.

Every brand-name price in this ledger was pulled directly from Novo Nordisk’s NovoCare Pharmacy site and Eli Lilly’s LillyDirect site. Novo Nordisk’s own November 2025 press release announcing its current self-pay pricing structure is a third source. Compounded pricing reflects commonly advertised rates across several compounded telehealth platforms, current as of this writing. The comparison deliberately avoids any single named compounded provider, since pricing and legal compliance vary by provider and change as FDA rules evolve. Always verify a specific provider’s current pricing and licensing status directly before choosing one. Regulatory details come from the FDA’s own published statements and reporting from Pharmacy Times. Nothing here substitutes for a licensed clinician’s guidance, consistent with our editorial standards.

Common questions on compounded vs brand name GLP-1

Why is compounded still legal if the FDA shortage is over?
Because the legal basis narrowed rather than disappeared. 503A pharmacies can still compound personalized, non-standard doses for a documented individual medical need. What’s no longer broadly permitted is mass-producing exact copies of the commercial product for anyone who orders one.

Is the price gap between compounded and brand-name still worth it?
It’s much smaller than it used to be. Compounded semaglutide runs about 57% of the Wegovy pen’s self-pay price, and it costs more than the Wegovy pill’s $149 starting tier. Compounded tirzepatide is now within roughly 20% of Zepbound’s own direct-to-consumer price. Weigh that against the regulatory narrowing above rather than treating it as a simple discount with no other differences.

Does insurance change this math?
Often significantly. A commercial-insurance manufacturer savings card can bring brand-name Wegovy or Zepbound down to a small fraction of the self-pay prices in this ledger for eligible patients. This ledger covers cash self-pay because that’s the price point compounded options compete on. Check your own coverage before assuming either self-pay number applies to you.

Ready to compare actual telehealth programs on service and support rather than just the medication line? Start with our GLP-1 telehealth head-to-head.